Cyclopharma announces the Approval of the French National Agency for medicinal product and health products for the use of its new radiopharmaceutical marker for breast cancer : EstroTep

Cyclopharma announces the Approval of the French National Agency for medicinal product and health products (ANSM) for the use of its new radiopharmaceutical marker bringing an innovative approach in breast cancer: EstroTep, injectable solution based on Fluoroestradiol [18F].

EstroTep is a marker similar to estrogen which fixes oneself on their receptors targets. The combined use of PET scan and EstroTep enables to visualize the biologic availability of estrogen receptors in vivo, in order to provide to clinicians a decision support for the orientation of the patient towards hormonal therapy.

Download the press release here.